Correction of Psychoemotional Disorders and Short-Term Prognosis in Patients with COVID-19.

Autor: Shishkova VN; National Medical Research Center for Therapeutic and Preventive Medicine, Russian Ministry of Health, Moscow, Russia., Imamgayazova KE; National Medical Research Center for Therapeutic and Preventive Medicine, Russian Ministry of Health, Moscow, Russia., Kapustina LA; National Medical Research Center for Therapeutic and Preventive Medicine, Russian Ministry of Health, Moscow, Russia.
Jazyk: angličtina
Zdroj: Neuroscience and behavioral physiology [Neurosci Behav Physiol] 2022; Vol. 52 (9), pp. 1373-1378. Date of Electronic Publication: 2023 Feb 21.
DOI: 10.1007/s11055-023-01369-w
Abstrakt: This review discusses the importance of the main psychoemotional risk factors for the development of chronic noncommunicable diseases. Current data on the prevalence of anxiety and depressive disorders in patients with cardiovascular disease (CVD) are presented. Data on the relationship between the development of psychoemotional disorders and CVD are summarized and the prospects for managing such patients within the framework of interdisciplinary cooperation are discussed. The main pathogenetic mechanisms for the development of complications, including CNS damage in COVID-19, are considered. The significance of the selection of pathogenetic therapy for patients with comorbid somatic and mental diseases in the context of the COVID-19 pandemic is discussed. Results from multicenter placebo-controlled studies of the use of fluvoxamine in patients with COVID-19 of varying severity are addressed.
(© Springer Nature Switzerland AG 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.)
Databáze: MEDLINE
Externí odkaz: